HC Wainwright Reiterates “Buy” Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $18.00 target price on the stock.

Several other equities research analysts have also issued reports on TNYA. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reduced their price objective on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $16.00 price target on shares of Tenaya Therapeutics in a report on Friday, October 18th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $14.75.

Tenaya Therapeutics Price Performance

Shares of NASDAQ TNYA traded up $0.37 during mid-day trading on Monday, reaching $2.75. The company’s stock had a trading volume of 3,091,500 shares, compared to its average volume of 921,765. The firm has a market capitalization of $217.86 million, a PE ratio of -1.90 and a beta of 2.34. The stock has a fifty day moving average of $2.02 and a two-hundred day moving average of $2.86. Tenaya Therapeutics has a 52 week low of $1.61 and a 52 week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Analysts anticipate that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors have recently made changes to their positions in TNYA. SG Americas Securities LLC acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth $49,000. The Manufacturers Life Insurance Company boosted its position in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Tenaya Therapeutics in the 2nd quarter worth $74,000. XTX Topco Ltd boosted its position in shares of Tenaya Therapeutics by 51.2% in the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth $134,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.